Physician profile
David Drenning
NPI 1437129152
$31,035.60
in general payments reported to CMS, 2019-2025
34 companies · $1,357 in 2025
The $1,357 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $3,130 · 2021: $2,014 · 2022: $1,411 · 2023: $1,923 · 2024: $2,202 · 2025: $1,357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,483.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,482.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $18,668.03 | 2019-2025 | |
| Medtronic Vascular, INC. | $2,118.40 | 2020 | |
| Janssen Pharmaceuticals, INC | $1,299.15 | 2019-2024 | Xarelto |
| Amgen INC. | $1,278.42 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $949.19 | 2019-2025 | Wainua, Farxiga, Brilinta |
| Boston Scientific Corporation | $859.16 | 2019-2025 | Avvigo Guidance System, Watchman Access System, Resonate El Icd Vr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $650.10 | 2019-2025 | Jardiance |
| Abbott Laboratories | $629.55 | 2021-2025 | Gallant, Optis, Jot Dx |
| Pfizer INC. | $623.76 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $618.35 | 2019-2024 | Camzyos, Eliquis |
| Regeneron Healthcare Solutions, INC. | $405.99 | 2019-2025 | Evkeeza, Praluent |
| Sanofi-Aventis U.S. LLC | $369.42 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $356.78 | 2022-2025 | Verquvo |
| Novo Nordisk INC | $350.65 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $301.20 | 2020-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $284.43 | 2019-2025 | Lifevest |
| Medtronic, INC. | $271.73 | 2021-2025 | Onyx Frontier, Spiderfx, In.Pact Admiral |
| Esperion Therapeutics, INC. | $233.04 | 2021-2025 | Nexletol |
| United Therapeutics Corporation | $154.01 | 2024-2025 | Tyvaso, Orenitram, Remodulin |
| Gilead Sciences, INC. | $143.49 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $86.30 | 2019 | |
| Cardiovascular Systems INC. | $67.36 | 2019-2022 | |
| Abiomed | $44.40 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $43.86 | 2023 | Uptravi |
| Terumo Medical Corporation | $35.50 | 2024 | Glidewire, Glidesheath Slender, Heartrail |
| Cvrx, INC. | $33.42 | 2022 | |
| Scpharmaceuticals INC. | $32.84 | 2024 | |
| Ge Healthcare | $24.76 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $22.39 | 2023 | Inpefa |
| Alnylam Pharmaceuticals INC. | $18.05 | 2025 | Amvuttra |
| Chiesi USA, INC. | $17.47 | 2020 | |
| Idorsia Pharmaceuticals US INC | $16.76 | 2024 | Tryvio |
| Recor Medical INC | $15.96 | 2025 | Paradise Ultrasound Renal Denervation System |
| Kowa Pharmaceuticals America, INC. | $11.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Drenning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.